R&D

R&D Pipeline

R&D

HL Genomics’ growth is rooted in continuous research and development.
We are committed to showcasing innovative technologies that lead the global pharmaceutical industry.

Pipeline

New Drug Pipeline

← Swipe left or right to see more →
Project Name Indication Development Stage
HL267 Macular Degeneration '24 Production of API for domestic clinical trials
'25 IND submission for domestic Phase 1 clinical trial
HL262 Dry Eye Syndrome '23 Production of API for domestic Phase 1 trial
'24 IND approval for domestic Phase 1 trial
'25 Production of API for domestic Phase 2 trial, US Phase 2 IND approval
'26 Planned IND submission for domestic Phase 2 trial
'28 Planned IND submission for domestic Phase 3 trial
HL235-1 Osteoporosis '27 Planned production of API for preclinical and domestic Phase 1 trials

Salt Modification

← Swipe left or right to see more →
Project Name Indication Development Stage
Vortioxetine. HCl Depression '25 PV Completed
'26 DMF Registration Completed
'27 Scheduled for Launch

Generics

← Swipe left or right to see more →
Project Name Indication Development Stage
Lifitegrast Dry Eye '24 Pilot for research completed
'26 PQ for research scheduled
Tegoprazan Gastric Ulcer
Gastroesophageal Reflux Disease		 '25 Pilot for research completed
NHS-Fluorescein Fluorescent excipient for lacrimal canaliculus inserts Under development
Cenobamate Epilepsy Under development
Gemigliptin tartrate Type 2 Diabetes Under development
Upadacitinib Arthritis, Colitis, Atopic Dermatitis Under development
Baricitinib Arthritis, Alopecia Areata, Atopic Dermatitis Under development
Pafolacianine Fluorescent contrast agent
(Ovarian cancer, Lung cancer)		 Under development
Fluorescein sodium Fluorescent contrast agent
(Diagnostic use for angiography)		 Under development
Indigo carmine Fluorescent contrast agent
(Renal function test)		 Under development
Methylene blue Methemoglobinemia Under development